Company intelligence / Profile preview

Reprixys Pharmaceutical Corporation

Ownership: Private
Development stage: Phase 2

Overview

Reprixys Pharmaceutical Corporation developed SelG1, a monoclonal antibody targeting P-selectin, for the prevention and reduction of vaso-occlusive pain crises in patients with sickle cell disease. A multicenter, randomized, placebo-controlled Phase II study demonstrated safety and efficacy endpoints for SelG1 with or without hydroxyurea therapy. The drug works by preventing blood cells from sticking together and blocking small vessels. No further late-stage results or approvals are publicly available.

Therapeutic areas: Hematology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

1 asset

SELG1

Phase 2

Indications: Sickle cell disease

Partnerships

None publicly disclosed as of January 2025; no major pharma partnerships listed.

Beyond the preview

Go deeper on Reprixys Pharmaceutical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reprixys Pharmaceutical Corporation.

Explore the full profile